^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)

    i
    Other names: BUB1B, BUB1 Mitotic Checkpoint Serine/Threonine Kinase B, Mitotic Checkpoint Serine/Threonine-Protein Kinase BUB1 Beta, MAD3/BUB1-Related Protein Kinase, Mitotic Checkpoint Kinase MAD3L, HBUBR1, BUBR1, MAD3L, SSK1, Budding Uninhibited By Benzimidazoles 1 (Yeast Homolog), Beta, Budding Uninhibited By Benzimidazoles 1 Homolog Beta (Yeast), Budding Uninhibited By Benzimidazoles 1 Homolog Beta, BUB1B, Mitotic Checkpoint Serine/Threonine Kinase, Protein SSK1, BUB1beta, Bub1A, MVA1
    Associations

    News

    Trials
    17d
    Liver fibrosis in biliary atresia: identification of the key gene EDIL3 via integrated bioinformatics. (PubMed, Front Med (Lausanne))
    Discoidin I-like domain 3 is a novel gene with a potentially key role in BA-related liver fibrosis, possibly influencing the proliferation and apoptosis of cholangiocytes by regulating the PI3K-AKT signaling pathway, thereby participating in the occurrence and development of liver fibrosis. This study provides new insights into the molecular mechanisms and potential treatment strategies for BA.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TOP2A (DNA topoisomerase 2-alpha) • TNFA (Tumor Necrosis Factor-Alpha) • PLK4 (Polo Like Kinase 4) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • EDIL3 (EGF Like Repeats And Discoidin Domains 3) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    1m
    Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential. (PubMed, Leuk Lymphoma)
    This FOXM1-BUB1B pathway is a promising therapeutic target, with inhibitors under preclinical investigation. Future research must validate its clinical relevance, explore combination therapies, and assess its potential as a biomarker to overcome challenges like toxicity and resistance.
    Review • Journal
    |
    FOXM1 (Forkhead Box M1) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
    1m
    Transcriptomics driven identification of hub gene miRNA interactions for biomarker and therapeutic target discovery in gynecological cancers. (PubMed, Front Oncol)
    The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • TGFB1 (Transforming Growth Factor Beta 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR381 (MicroRNA 381) • MIR495 (MicroRNA 495) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8) • MIR653 (MicroRNA 653)
    1m
    Identification of hub genes and construction of a survival prediction model for patients with nasopharyngeal carcinoma. (PubMed, Sci Rep)
    The results of the receiver operating characteristic (ROC) curve, area under the ROC curve, calibration plot, net reclassification index, integrated discrimination improvement index, and decision curve analysis revealed that the model had good discriminating ability, predictive ability, and clinical utility. In conclusion, AURKA, BUB1, and CDK1 are potential prognostic biomarkers of NPC, and a prediction model incorporating the expression levels of AURKA and BUB1 has good discriminating ability, predictive ability, and clinical utility.
    Journal
    |
    AURKA (Aurora kinase A) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
    1m
    Targeting the splicing factor CWC22 induces mitotic slippage through repression of BubR1 expression and CDK1 activity in cancer cells. (PubMed, J Biol Chem)
    These results suggest that highly expressed CWC22 contributes to the progression of G2/M phase and prevents mitotic slippage-caused whole-genome doubling by maintaining the SAC function and CDK1 activity in cancer cells. These findings reveal a novel splicing factor function in mitotic checkpoint signaling, which enables uncontrolled cell proliferation in CWC22-overexpressing cancer cells.
    Journal
    |
    WEE1 (WEE1 G2 Checkpoint Kinase) • CDK1 (Cyclin-dependent kinase 1) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1)
    1m
    Linking kinetochore attachment to checkpoint control: the role of Aurora B in BubR1 acetylation. (PubMed, Nucleic Acids Res)
    Disruption of Aurora B-mediated phosphorylation compromises K250 acetylation, fibrous corona maintenance, and MCC stability, whereas expression of a K250 acetylation-mimetic BubR1 rescues these defects in S16A/S39A phosphorylation-deficient mutants. Together, our findings establish a phosphorylation-acetylation cascade in BubR1 as a critical SAC signaling pathway and identify this axis as a promising therapeutic target in cancers driven by chromosomal instability.
    Journal
    |
    BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    2ms
    Targeting BUB1B-Driven Cancer stemness in lung adenocarcinoma: a novel therapeutic strategy via PI3K/AKT pathway modulation. (PubMed, Expert Opin Ther Targets)
    BUB1B serves as a pivotal regulator of LUAD stemness and malignancy, linking mRNAsi with clinical features, immune context, and genomic alterations. These findings support BUB1B as a promising diagnostic, prognostic, and therapeutic biomarker, though multicenter validation is needed.
    Journal
    |
    BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B)
    2ms
    Radiotherapy and precision medicine's role in molecular alterations during chromosomal division: The influence of MB, TP53, CENPA, BUB1B, MAD2L1, ZWINT expression and noncoding RNAs in oral cancer. (PubMed, Biochem Biophys Rep)
    Additionally, we explore the potential of targeting these molecules to enhance the efficacy of radiation therapy and improve patient outcomes. Our study contributes to the comprehension of the molecular processes underlying oral cancer and provides insights into the development of novel therapeutic strategies based on personalized medicine.
    Journal
    |
    TP53 (Tumor protein P53) • MIR361 (MicroRNA 361) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CENPA (Centromere protein A) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MIR122 (MicroRNA 122) • ZWINT (ZW10 Interacting Kinetochore Protein)
    3ms
    Cyclin B2 facilitates glycolysis and tumor progression in pancreatic ductal adenocarcinoma by promoting histone lactylation. (PubMed, BMC Cancer)
    The glycolysis-CCNB2-H3K18la-TTK/BUB1B signaling axis exacerbates the malignant progression of PDAC, providing insights into potential lactylation-based therapeutic strategies for this disease.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • LDHB (L-lactate dehydrogenase B chain) • CCNB2 (Cyclin B2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1) • TTK (TTK Protein Kinase)